plamotamab (XmAb13676)

P1, N=270, Active, not recruiting, Xencor, Inc. | Recruiting --> Active, not recruiting

In the trials, mosunetuzumab, glofitamab, epcoritamab, odronextamab, IGM-2323, and plamotamab were identified as antiCD20-CD3 bsAbs, which are evaluated against RRDLBCL as monotherapy and in combination regimens (Table). Based on our analysis , antiCD20-CD3 bsAbs are safe and efficacious. Among these drugs, glofitamab, epcoritamab and odronextamab as monotherapy and/or in combination regimens are the most effective therapies against RRDLBCL. Drug (s) **Author Efficac y ORR, CR per Lugano/RR C for ML criteria **CRS Overall/G 3 per ASTCT/ Lee et al criteria Overall Toxicity G≥3 per CTCAE CNS Toxicity G≥3 Per CTCAE aNHL 35%Mosun IV Budde et al.

P2, N=3, Terminated, Xencor, Inc. | N=240 --> 3 | Trial completion date: Jun 2031 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Dec 2022; The study has been terminated early by the sponsor due to business decision.

Plamotamab demonstrated evidence of clinical activity in heavily pretreated pts with DLBCL and FL with promising responses in pts with prior CAR-T therapy. CRS was generally manageable with premedication. Safety and efficacy evaluation of pts at the RD is currently ongoing, and updated results will be provided.

P2, N=240, Recruiting, Xencor, Inc. | Not yet recruiting --> Recruiting

P2, N=240, Not yet recruiting, Xencor, Inc.

No abstract available

Cytokine release syndrome (CRS) prophylaxis with dexamethasone, antihistamine, and acetaminophen was mandated prior to each administration of plamotamab. Plamotamab demonstrated evidence of clinical activity in heavily pretreated subjects with R/R NHL. CRS was generally manageable with premedication. The study is ongoing with further optimization of dose and schedule.